http://byetta.legalview.com/msn/ 2012-02-23 http://byetta.legalview.com/msn/roche-dumps-taspo-as-analysts-read-last-rites/1279295/ 2012-02-23 http://byetta.legalview.com/msn/roche-said-to-return-diabetes-drug-rights-to-ipsen/1279294/ 2012-02-23 http://byetta.legalview.com/msn/nice-issues-its-final-appraisal-determination-fad-on-the-use-of-victoz/1235893/ 2012-02-23 http://byetta.legalview.com/msn/roche-halts-taspoglutide-dosing-in-final-studies/1235892/ 2012-02-23 http://byetta.legalview.com/msn/roche-stops-giving-diabetes-drug-in-final-trial-over-nausea-side-effec/1235891/ 2012-02-23 http://byetta.legalview.com/msn/once-weekly-exenatide-vs-sitagliptin-or-pioglitazone-for-type-2-diabet/1235890/ 2012-02-23 http://byetta.legalview.com/msn/barclays-maintains-an-overweight-rating-on-amylin-pharmaceuticals-amln/1235889/ 2012-02-23 http://byetta.legalview.com/msn/amylin-shares-dip-on-diabetes-drug-study-results/1197970/ 2012-02-23 http://byetta.legalview.com/msn/amylin-shares-rise-ahead-of-diabetes-meeting/1197969/ 2012-02-23 http://byetta.legalview.com/msn/amylin-shares-fall-after-new-bydureon-data-hits/1197968/ 2012-02-23 http://byetta.legalview.com/msn/amylin-drug-trial-success-is-mixed/1197967/ 2012-02-23 http://byetta.legalview.com/msn/duration-4-study-results-bydureon-efficacy-and-tolerability-profile-ex/1197966/ 2012-02-23 http://byetta.legalview.com/msn/a-drop-on-bad-news-but-it-was-a-long-shot-anyway/1197965/ 2012-02-23 http://byetta.legalview.com/msn/biotech-reports-record-financial-results-for-2010-first/1159841/ 2012-02-23 http://byetta.legalview.com/msn/redpoint-sitting-in-the-sweet-spot/1159840/ 2012-02-23 http://byetta.legalview.com/msn/fda-approved-diabetes-drug-despite-hints-at-cancer-risk/1159839/ 2012-02-23 http://byetta.legalview.com/msn/biotech-posts-strong-first-quarter-gain/1159838/ 2012-02-23 http://byetta.legalview.com/msn/takeda-amylin-to-co-develop-obesity-drugs/1132295/ 2012-02-23 http://byetta.legalview.com/msn/novo-nordisk-ceo-hopeful-on-us-victoza-approval/1132294/ 2012-02-23 http://byetta.legalview.com/msn/reuters-summit-update-1-novo-ceo-hopeful-on-victoza-approval/1132293/ 2012-02-23 http://byetta.legalview.com/msn/nationalism-and-the-akwanshi-2-121109/1132292/ 2012-02-23 http://byetta.legalview.com/msn/diabetes-cases-of-hemorrhagic-or-necrotizing-pancreatitis-associated/1132291/ 2012-02-23 http://byetta.legalview.com/msn/fda-issues-warning-on-diabetes-drug/1132290/ 2012-02-23 http://byetta.legalview.com/msn/how-to-have-fun-growing-a-baby/1110187/ 2012-02-23 http://byetta.legalview.com/msn/ignore-these-companies-at-your-peril/1110186/ 2012-02-23 http://byetta.legalview.com/msn/the-roller-coaster-stock-that-keeps-on-giving/1110185/ 2012-02-23 http://byetta.legalview.com/msn/lilly-makes-buyout-offer-to-4000-sales-reps/1110184/ 2012-02-23 http://byetta.legalview.com/msn/cnbcs-most-shared/1110183/ 2012-02-23 http://byetta.legalview.com/msn/marvin-bohn-circa-2007/1110182/ 2012-02-23 http://byetta.legalview.com/msn/diabetes-drug-byetta-may-aid-weight-loss-in-obese-patients/1110181/ 2012-02-23 http://byetta.legalview.com/msn/pharmas-market-video/1110180/ 2012-02-23